TuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to “Sell”

TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Other analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $9.00.

TuHURA Biosciences Stock Up 2.8%

NASDAQ HURA opened at $1.45 on Tuesday. The stock has a market capitalization of $92.19 million, a PE ratio of -2.30 and a beta of -0.32. The company has a 50 day moving average price of $1.41 and a two-hundred day moving average price of $1.61. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $4.44.

TuHURA Biosciences (NASDAQ:HURA) last posted its earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds have recently added to or reduced their stakes in HURA. Barclays PLC raised its position in shares of TuHURA Biosciences by 42.6% in the 4th quarter. Barclays PLC now owns 52,615 shares of the company’s stock valued at $40,000 after acquiring an additional 15,725 shares during the period. State Street Corp grew its stake in shares of TuHURA Biosciences by 4.9% during the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after acquiring an additional 13,594 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of TuHURA Biosciences by 109.0% during the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after acquiring an additional 19,931 shares in the last quarter. Deutsche Bank AG grew its stake in shares of TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after acquiring an additional 54,051 shares in the last quarter. Finally, Invst LLC grew its stake in shares of TuHURA Biosciences by 88.9% during the 4th quarter. Invst LLC now owns 42,506 shares of the company’s stock worth $32,000 after acquiring an additional 20,006 shares in the last quarter. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.